Professor Michelle Lockley and Dr Oliver Pearce have both been awarded prestigious Programme Foundation Awards from Cancer Research UK, worth nearly £1.5 million each, to support the work of their research groups at Barts Cancer Institute, Queen Mary University of London.
Adaptive chemotherapy can prolong survival in lab models of ovarian cancer, according to new results. The findings could pave the way for a more effective and gentler approach to treating ovarian cancer that uses existing drugs in a more intelligent way.
A new technique produces stunning, nebula-like images of tumours that provide crucial insights into cancer, how it behaves and how our immune cells attempt to fight it.